Cytidine
CAS 65-46-3
Cytidine (CAS 65-46-3) is a Phase 3 pharmaceutical compound with 4 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 16700 nM | 24 | - |
| - | IC50 | 1.5566666666666666 ug.mL-1 | 6 | - |
| - | EC50 | 25192.5 nM | 2 | - |
| - | Potency | 28294.45 nM | 2 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Cytidine used for in pharmaceutical contexts?
Cytidine (CAS 65-46-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Cytidine?
No adverse-event association or SIDER side-effect rows are rendered for Cytidine in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Cytidine also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Cytidine with EU status "permitted".
What clinical phase is Cytidine in?
Cytidine is rendered with ChEMBL max phase 3.